Interactions of corticotropin-releasing factor with antidepressant and anxiolytic drugs: behavioral studies with pigeons.
A number of studies have shown significant interactions between neuronal systems involved with corticotropin-releasing factor (CRF) and either the clinical manifestations of depression and anxiety or the effects of antidepressant or anxiolytic drugs. In the present study, effects of CRF were studied alone and in combination with imipramine and with the sedative-hypnotic/anxiolytic drugs pentobarbital and chlordiazepoxide. Interactions of CRF with the novel, atypical anxiolytic buspirone were also examined. Interactions were evaluated through the use of schedule-controlled responding, responding suppressed by punishment, and drug discrimination procedures using the conditioned key-pecking response of pigeons. Effects of CRF were significantly enhanced when given in combination with imipramine with low noneffective imipramine doses potentiating the rate-reducing effects of CRF. Similarly, in pigeons trained to discriminate imipramine from saline, noneffective doses of CRF shifted the imipramine dose-response curve more than twofold to the left. Low doses of imipramine that produced saline key responding, produced imipramine-key responding when coadministered with CRF. The CRF antagonist alpha-helical CRF9-41 did not alter the rate-decreasing effects of imipramine. Effects of CRF on schedule-controlled responding were, however, antagonized by the administration of chlordiazepoxide and pentobarbital but not by buspirone, suggesting that CRF interacts with the GABA/benzodiazepine receptor mechanism complex but not with those systems involved in mediating the effects of buspirone. These results suggest that CRF interacts in significant ways with specific neurotransmitter systems subserving depression and anxiety.
Zhang
L
L
Department of Psychiatry, Uniformed Services University of the Health Sciences, Bethesda, MD 20814-4799.
Barrett
J E
JE
D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D000928:Antidepressive Agents / Q000494:pharmacology*; D001070:Appetitive Behavior / Q000187:drug effects; D001143:Arousal / Q000187:drug effects*; D001362:Avoidance Learning / Q000187:drug effects; D001522:Behavior, Animal / Q000187:drug effects*; D002065:Buspirone / Q000494:pharmacology; D002352:Carrier Proteins; D002707:Chlordiazepoxide / Q000494:pharmacology; D003118:Color Perception / Q000187:drug effects; D010856:Columbidae; D003214:Conditioning, Classical / Q000187:drug effects; D003346:Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D004193:Discrimination Learning / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects*; D007099:Imipramine / Q000494:pharmacology; D010424:Pentobarbital / Q000494:pharmacology; D010446:Peptide Fragments / Q000494:pharmacology; D010913:Pituitary-Adrenal System / Q000187:drug effects*; D011955:Receptors, Drug; D017981:Receptors, Neurotransmitter / Q000187:drug effects; D012055:Reinforcement Schedule
D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D002352:Carrier Proteins; D010446:Peptide Fragments; D011955:Receptors, Drug; D017981:Receptors, Neurotransmitter; C027775:imipramine receptor; D002707:Chlordiazepoxide; D003346:Corticotropin-Releasing Hormone; C045089:corticotropin releasing hormone (9-41); D010424:Pentobarbital; D007099:Imipramine; D002065:Buspirone